Without biomarker data, Editas results fail to impress

The first clinical efficacy data from Editas’ gene editing platform didn’t meet high expectations set by competitors in other applications, but the program wasn’t designed to deliver the same biomarker-based early reassurances.

Investors, patients and the rest of the industry will need to be more patient this time, and wait for additional clinical efficacy data that will give a better indication of whether the therapy works...